Login to Your Account



BREEZE 3 Trial Results Chill Depomed's Hot Flash Drug

By Catherine Shaffer


Monday, October 17, 2011
Disappointing top-line results from a third Phase III trial of Depomed Inc.'s Serada cast a shadow on the drug's prospects with the FDA. The trial studied frequency and severity of hot flash episodes in menopausal women after four weeks, 12 weeks and 24 weeks.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription